| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/21/2014 | US8633205 Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein kinases |
| 01/21/2014 | US8633202 Crystalline levofolinic acid and process for its preparation |
| 01/21/2014 | US8633185 Pyrrolobenzodiazepines |
| 01/21/2014 | US8632824 Process of obtaining thylakoids from photosynthetic organisms; plant fractions obtained from the process; pure thylakoids; and methods of use of thylakoids as ROS scavengers, photo-protectors, biosensors, biofilters and bioreactors |
| 01/21/2014 | US8632789 System and method for delivery of DNA-binding chemotherapy drugs using nanoparticles |
| 01/21/2014 | US8632788 Parenteral formulation for epothilone analogs |
| 01/21/2014 | US8632751 Scanning suspension comprising a particle with a diameter of at least 1 micrometer |
| 01/21/2014 | CA2739604C Targeted liposome gene delivery |
| 01/21/2014 | CA2698396C Interferon alpha2a modified by polyethylene glycol, the preparation and use thereof |
| 01/21/2014 | CA2657096C Human protein tyrosine phosphatase inhibitors and methods of use |
| 01/21/2014 | CA2628747C Combinations of hormone therapy agents and metalloprotease inhibitors for the treatment of cancer |
| 01/21/2014 | CA2605050C Histone deacetylase inhibitors |
| 01/21/2014 | CA2600637C Tetrahydro- and dihydroquinazolinones |
| 01/21/2014 | CA2484398C Method for reducing pain using oncolytic viruses |
| 01/21/2014 | CA2446723C Antibodies that immunospecifically bind to trail receptors |
| 01/21/2014 | CA2418014C Immunotherapy for chronic myelocytic leukemia |
| 01/21/2014 | CA2359317C Method of treating restenosis by antisense targeting of c-myc |
| 01/21/2014 | CA2341763C Antigenic peptides of aglyco 10b and antibodies thereto |
| 01/21/2014 | CA2236868C Conditionally replicating viral vectors and their use |
| 01/16/2014 | WO2014012117A1 Compositions and methods for localized drug delivery through mammary papillae |
| 01/16/2014 | WO2014011974A1 Imidazotriazinecarbonitriles useful as kinase inhibitors |
| 01/16/2014 | WO2014011902A1 Irak inhibitors and uses thereof |
| 01/16/2014 | WO2014011863A1 Method of treatment with 3-cyclopropylcarbonyl-3,6-diazabicyclo[3.1.1]heptane |
| 01/16/2014 | WO2014011712A1 Iap antagonists |
| 01/16/2014 | WO2014011568A1 Azaindole derivatives which act as pi3k inhibitors |
| 01/16/2014 | WO2014011521A1 Immunoconjugates comprising anti - cd79b antibodies |
| 01/16/2014 | WO2014011520A1 Immunoconjugates comprising anti-cd22 antibodies |
| 01/16/2014 | WO2014011519A1 Immunoconjugates comprising anti-cd79b antibodies |
| 01/16/2014 | WO2014011518A1 Immunoconjugates comprising anti-cd22 antibodies |
| 01/16/2014 | WO2014011284A1 Method of treating gastrointestinal stromal tumors |
| 01/16/2014 | WO2014011177A1 Antisense p53 phosphorodiamidate morpholino composititons, methods and indications |
| 01/16/2014 | WO2014011120A1 Endoperoxides, synthesis and uses thereof for the treatment of neoplastic diseases such as cancer |
| 01/16/2014 | WO2014011072A1 Producer of newcastle disease virus strain ndv/anas crecca/omsk/9/2010 usable for producing a candidate anti-cancer preparation on the basis thereof |
| 01/16/2014 | WO2014010948A1 Pharmaceutical composition comprising azathioprine as active ingredient for preventing or treating brain tumors or temodal-resistant glioblastomas |
| 01/16/2014 | WO2014010758A1 Anti-tumour agent, marker for tumour detection, and oral vaccine agent |
| 01/16/2014 | WO2014010742A1 Pharmaceutical composition or food product composition comprising monogalactosyldiacylglycerol or pharmaceutically acceptable salt thereof as active ingredient |
| 01/16/2014 | WO2014010718A1 Chiral nucleic acid adjuvant |
| 01/16/2014 | WO2014010528A1 Oxaliplatin-containing pharmaceutical composition |
| 01/16/2014 | WO2014010232A1 Ly6k epitope peptides for th1 cells and vaccines containing the same |
| 01/16/2014 | WO2014010231A1 Kif20a epitope peptides for th1 cells and vaccines containing the same |
| 01/16/2014 | WO2014010229A1 Cdca1 epitope peptides for th1 cells and vaccines containing the same |
| 01/16/2014 | WO2014009891A1 Heterocyclic compounds for use in the treatment of cancers |
| 01/16/2014 | WO2014009872A1 Tetrahydroquinazolinone derivatives as parp inhibitors |
| 01/16/2014 | WO2014009774A1 Conjugates of cell binding molecules with cytotoxic agents |
| 01/16/2014 | WO2014009609A1 Combination therapy iii |
| 01/16/2014 | WO2014009500A1 Anti-tumoral composition comprising the compound 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea |
| 01/16/2014 | WO2014009496A1 Cancer treatment |
| 01/16/2014 | WO2014009495A1 Antiproliferative benzo [b] azepin- 2 - ones |
| 01/16/2014 | WO2014009319A1 Indolinone derivatives anticancer compounds |
| 01/16/2014 | WO2014009318A1 3-{3-[1 -(4-dimethylaminomethyl-phenylamino)-1 -phenyl-meth-(z)-ylidene]-2-oxo-2,3-dihydro-1 h-indol-6-yll-propynoic acid ethylamide and its use in the treatment of cancer |
| 01/16/2014 | WO2014009222A1 Combination therapy for the treatment of cancer and immunosuppression |
| 01/16/2014 | WO2014009219A1 Method for preparing substituted triazolopyridines |
| 01/16/2014 | WO2014008838A1 Bis-indolylacetic acid derivative attached with aryl substituted methyl, and preparation method and use thereof |
| 01/16/2014 | WO2014008794A1 Crystalline form i of tyrosine kinase inhibitor dimaleate and preparation methods thereof |
| 01/16/2014 | WO2014008708A1 Treatment method for dissolving tumour and transforming cancer cells with phenol and quinone |
| 01/16/2014 | WO2014008673A1 Allopurinol derivative and preparation method and application thereof |
| 01/16/2014 | WO2014008612A1 Method for inducing immune tolerance using non-proliferative polymer-modified allogeneic leukocytes |
| 01/16/2014 | WO2014008594A1 System and method for using ultrasound-stimulated microbubble exposures to induce ceramide accumulation in endothelial and tumor cells |
| 01/16/2014 | WO2014008592A1 Combinations comprising diamidine compounds and parp inhibitors for use iν treating cancer |
| 01/16/2014 | WO2013177187A3 Synergistic tumor treatment with extended-pk il-2 and therapeutic agents |
| 01/16/2014 | WO2013175474A3 Selective inhibitors of undifferentiated cells |
| 01/16/2014 | WO2013131093A9 The use of a panel of urinary cytokines to predict response to bcg therapy for bladder cancer |
| 01/16/2014 | WO2012174487A8 Bromodomain inhibitors and uses thereof |
| 01/16/2014 | US20140018360 Azaindenoisoquinoline topoisomerase i inhibitors |
| 01/16/2014 | US20140017774 Pca3, pca3 genes, and methods of use |
| 01/16/2014 | US20140017273 Albumin-Fused Anti-Angiogenesis Peptides |
| 01/16/2014 | US20140017243 Use of adcc-optimized antibodies for treating weak patients |
| 01/16/2014 | US20140017236 Methods for treating interleukin-6 related diseases |
| 01/16/2014 | CA2877187A1 Antiproliferative benzo [b]azepin-2-ones |
| 01/16/2014 | CA2876884A1 Crystalline form i of tyrosine kinase inhibitor dimaleate and preparation methods thereof |
| 01/16/2014 | CA2876730A1 Enhancing activity of car t cells by co-introducing a bispecific antibody |
| 01/16/2014 | CA2874904A1 Immunoconjugates comprising anti-cd22 antibodies |
| 01/16/2014 | CA2874856A1 Immunoconjugates comprising anti-cd79b antibodies |
| 01/15/2014 | EP2684957A2 Double-stranded siRNA targeting cancer antigen eEF2 |
| 01/15/2014 | EP2684885A1 Novel compounds obtained from gamboge resin, and medical uses of the same |
| 01/15/2014 | EP2684884A1 Novel compounds obtained from gamboge resin, and medical uses of the same |
| 01/15/2014 | EP2684883A1 Novel compounds obtained from gamboge resin, and medical uses of the same |
| 01/15/2014 | EP2684882A1 Novel compounds obtained from gamboge resin, and medical uses of the same |
| 01/15/2014 | EP2684880A1 Dispiropyrrolidine derivative |
| 01/15/2014 | EP2684877A2 Pharmaceutically acceptable salt of (e)-n-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2r)-1-methylpyrrolidin-2-yl]prop-2-enamide, preparation method therefor, and medical use thereof |
| 01/15/2014 | EP2684874A1 Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors |
| 01/15/2014 | EP2684573A2 Use of 5-aminolevulinic acid and derivatives in a solid form for photodynamic treatment and diagnosis |
| 01/15/2014 | EP2684566A1 Pharmaceutical composition for preventing and treating complications of diabetes containing a traditional oriental medicine extract or a fraction thereof as an active ingredient |
| 01/15/2014 | EP2683825A1 Methods of treating cancer by inhibition of dna repair proteins |
| 01/15/2014 | EP2683741A2 Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers |
| 01/15/2014 | EP2683740A2 Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution |
| 01/15/2014 | EP2683737A1 Extracellular targeted drug conjugates |
| 01/15/2014 | EP2683722A1 Fluorophenyl bicyclic heteroaryl compounds |
| 01/15/2014 | EP2683720A1 1H-PYROLLO[3,2-d]PYRIMIDINEDIONE DERIVATIVES |
| 01/15/2014 | EP2683716A1 Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
| 01/15/2014 | EP2683715A1 Pyrido [2, 3 - b]pyrazine derivatives and their therapeutical uses |
| 01/15/2014 | EP2683708A1 Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
| 01/15/2014 | EP2683694A1 Androgen receptor antagonists and uses thereof |
| 01/15/2014 | EP2683413A1 In vivo selection of therapeutically active antibodies |
| 01/15/2014 | EP2683412A2 Methods and materials for assessing responsiveness to lenalidomide, thalidomide, and/or other thalidomide analogs |
| 01/15/2014 | EP2683410A2 Targeted nanocarrier systems for delivery of actives across biological membranes |
| 01/15/2014 | EP2683409A1 Amatoxin-conjugates with improved linkages |
| 01/15/2014 | EP2683398A1 Compositions, methods and uses for radioprotectants |
| 01/15/2014 | EP2683386A2 Compounds and methods of use in ablative radiotherapy |
| 01/15/2014 | EP2683384A1 Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |